Stock KROS KEROS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Keros Therapeutics, Inc.

Equities

KROS

US4923271013

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
57.86 USD +6.77% Intraday chart for Keros Therapeutics, Inc. -0.72% +45.52%
03-19 Morphic Holding Names Simon Cooper as Chief Medical Officer MT
03-15 Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Morphic Holding Names Simon Cooper as Chief Medical Officer
MT
Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug
MT
Keros Therapeutics Gets FDA Fast Track Designation for Anemia Drug
MT
Keros Gets FDA Fast-Track Designation for Lead Drug KER-050
DJ
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
AQ
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
CI
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
AQ
Keros Therapeutics, Inc. Announces Resignation of Simon Cooper, M.B.B.S., as Chief Medical Officer, Effective March 12, 2024
CI
Keros Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Keros Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
AQ
Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q4 Revenue $143,000
MT
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
AQ
Keros Therapeutics Closes $151.3 Million Stock Offering
MT
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
AQ
Keros Therapeutics Prices Stock Offering at $40 a Share
MT
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
AQ
Keros Therapeutics Proposes $120 Million Common Stock Offering
MT
Keros Therapeutics Announces Proposed Public Offering of Common Stock
AQ
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KROS Stock
  4. News Keros Therapeutics, Inc.